Skip to main content

Advertisement

Table 2 Association of sSIGLEC-1 with clinical parameters of SLE

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Clinical parameter Combined EUR Non-EUR
N (total) ORa (95% CI) P valueb N (total) ORa (95% CI) P valueb N (total) ORa (95% CI) P valueb
Renal (nephritis) 156 1.53 (1.10–2.15) 0.01 75 1.65 (1.09–2.52) 0.02 81 1.16 (0.60–2.25) 0.67
Haematological 291 1.35 (0.95–1.92) 0.09 185 1.34 (0.80–2.20) 0.25 106 1.28 (0.72–2.25) 0.4
Biologicsc 35 1.20 (1.01–1.42) 0.04 23 1.18 (0.90–1.18) 0.19 12 0.95 (0.70–1.23) 0.71
Neurological 78 1.01 (0.76–1.34) 0.95 36 0.87 (0.63–1.18) 0.37 42 0.83 (0.39–1.76) 0.64
Admission 226 1.18 (0.81–1.71) 0.39 140 145 (0.90–2.37) 0.13 86 0.60 (0.30–1.21) 0.16
Corticosteroid use 302 0.98 (0.69–1.41) 0.96 174 0.96 (0.57–1.57) 0.86 128 0.88 (0.49–1.56) 0.35
  1. Association of sSIGLEC-1 concentration with clinical parameters recorded from SLE patients occurring since their disease diagnosis and up to the time of their visit
  2. CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus, sSIGLEC-1 soluble sialic acid binding Ig-like lectin 1
  3. aOdds ratio (OR) calculated on the group of patients with sSIGLEC levels > 95th percentile
  4. bP values were calculated in each group using a logistical regression model, where the SLE patients were divided into groups based on sSIGLEC1 serum level centiles (< 50th centile, 51st–74th centile, 75th–95th centile and > 95th centile)
  5. cPatients treated with biologic drugs at the time of visit